The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Kyowa Kirin
pharmaceutical company
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- The FDA recommended advancement for a new drug application submitted by a company.
- Ondine Biomedical Inc. is seeking a pre-NDA meeting with the FDA regarding LANTERN results while conducting clinical trials in the US and Canada.